STOCK TITAN

Lilly Eli & Co - LLY STOCK NEWS

Welcome to our dedicated page for Lilly Eli & Co news (Ticker: LLY), a resource for investors and traders seeking the latest updates and insights on Lilly Eli & Co stock.

Overview

Lilly Eli & Co (LLY) is a globally recognized pharmaceutical powerhouse with a heritage that spans nearly a century and a half. Founded in 1876 by Colonel Eli Lilly, the company has consistently transformed scientific research into life‐changing therapies while establishing itself as an authority in pharmaceutical innovation. Operating from its headquarters in Indianapolis, Indiana, Lilly Eli & Co has built a network that spans multiple continents and markets, embodying a commitment to advanced research and manufacturing excellence.

Business Model and Core Competencies

The company generates revenue primarily through the development, production, and global distribution of therapeutic medicines. Its diverse portfolio is underpinned by breakthrough R&D in biotechnology and chemical synthesis. By leveraging strategic investments in research, the company has developed innovative treatments for critical areas such as diabetes, oncology, immunology, and neuroscience. These initiatives not only address significant unmet medical needs but also strengthen its competitive edge in the highly dynamic pharmaceutical sector.

Innovative Research and Development

Lilly Eli & Co excels in turning cutting-edge scientific discoveries into practical, market-ready solutions. The company’s approach integrates state-of-the-art biotechnology, chemical innovation, and genetic medicine – elements that drive its robust R&D engine and pave the way for advances in areas such as targeted cancer therapies, metabolic management, and chronic disease care. Its research programs emphasize both precision medicine and large-scale production, ensuring that new therapies are both effective and accessible.

Global Manufacturing and Supply Chain Excellence

In addition to its research prowess, Lilly Eli & Co has a well-established global manufacturing network. The company has continually expanded its facilities, investing in advanced production capabilities to maintain a reliable supply chain. This commitment to manufacturing excellence helps ensure that high-quality products are delivered efficiently to patients worldwide, reinforcing its reputation as a dependable partner in healthcare.

Market Position and Competitive Edge

As an integrated leader in pharmaceutical technology and therapeutics, Lilly Eli & Co has positioned itself at the intersection of innovation and reliability. The company competes through a blend of long-term research investments, strategic global partnerships, and a relentless focus on improving patient outcomes. Its strong brand legacy and comprehensive portfolio of drugs underline a commitment to scientific excellence and unwavering operational execution.

Commitment to Quality and Patient-Centric Solutions

Quality and trust are central to the company's ethos. With a history of rigorous clinical trials and regulatory approvals, Lilly Eli & Co ensures that its medicines meet the highest standards of safety and efficacy. This patient-centric approach, combined with sustainable manufacturing practices, makes it a reliable source of advanced therapies, fostering long-term trust among healthcare providers and patients alike.

Industry Keywords and Expertise

Industry-specific terms such as pharmaceutical innovation, biotechnology, therapeutics, and advanced manufacturing are integral to understanding the company’s operations. These terms reflect the scientific depth and operational expertise that have allowed Lilly Eli & Co to remain at the forefront of drug discovery and development.

Conclusion

With its rich history, expansive R&D capabilities, and global operational reach, Lilly Eli & Co is a testament to the power of innovation in healthcare. This comprehensive overview highlights not only its diversified business model and advanced research but also its enduring commitment to enhancing patient lives through high-quality, accessible, and effective medicines.

Rhea-AI Summary

Eli Lilly reported Q1 2023 revenue of $6.96 billion, down 11% year-over-year, primarily due to a significant decline in COVID-19 antibody sales. Excluding these revenues, the company saw a 10% increase, driven by strong performances from its growth products like Mounjaro, Trulicity, Verzenio, and Jardiance. Q1 2023 EPS decreased 29% to $1.49 on a reported basis and 38% to $1.62 on a non-GAAP basis. The company raised its 2023 EPS guidance, now forecasting reported EPS between $8.18 to $8.38, reflecting positive core business growth and successful pipeline advancements, including FDA approvals. Eli Lilly's new products contributed $573.6 million to revenue, with growth products revenue rising 18% to $4.56 billion.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.74%
Tags
-
Rhea-AI Summary

Eli Lilly (NYSE: LLY) announced remarkable results from its SURMOUNT-2 trial, demonstrating that tirzepatide led to weight reductions of up to 15.7% (34.4 lb or 15.6 kg) in participants with obesity or overweight and type 2 diabetes over 72 weeks. The study met all co-primary and key secondary objectives, indicating tirzepatide's superiority over placebo. Notably, 81.6% (10 mg) and 86.4% (15 mg) of participants achieved at least 5% weight reduction, significantly higher than the 30.5% in the placebo group. The safety profile was consistent with previous trials, with gastrointestinal issues being the most common adverse events. Lilly plans to complete the FDA submission for tirzepatide in the coming weeks, expecting regulatory action by late 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.74%
Tags
none
-
News
Rhea-AI Summary

Eli Lilly (NYSE: LLY) has announced a definitive agreement to sell its glucagon product BAQSIMI to Amphastar Pharmaceuticals (NASDAQ: AMPH) for $500 million at closing and an additional $125 million after one year. This divestiture aims to enhance the accessibility of BAQSIMI, the first nasal glucagon treatment for severe hypoglycemia in diabetes patients. BAQSIMI generated worldwide sales of $139.3 million in 2022, and the deal is expected to close in Q2 or Q3 2023. Both companies' boards have approved the agreement, which includes potential sales-based milestone payments of up to $450 million. Amphastar plans to invest in BAQSIMI to improve treatment access for those on insulin, aligning with its strategic focus on expanding its diabetes portfolio.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.49%
Tags
none
Rhea-AI Summary

Eli Lilly (NYSE: LLY) announced an unprecedented $3.7 billion investment in manufacturing facilities in Boone County, Indiana. This commitment includes an additional $1.6 billion and the creation of 200 new jobs, totaling up to 700 jobs at the site. The investment marks the largest manufacturing expansion in the company’s history and aims to utilize advanced technology for producing innovative medicines.

Additionally, Lilly will allocate $15 million to the Ivy Tech Foundation over five years, funding 1,000 scholarships for students pursuing careers in pharmaceutical manufacturing. The initiative promotes education and employment for individuals from diverse backgrounds and supports the state's talent pipeline.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.64%
Tags
none
-
Rhea-AI Summary

Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter regarding the biologic license application for mirikizumab, a treatment for ulcerative colitis (UC). The FDA's letter highlighted manufacturing issues but did not raise concerns about clinical data or safety. Lilly expressed confidence in mirikizumab's Phase 3 clinical data and aims for a swift resolution with the FDA. Recently, mirikizumab was approved in Japan as a first-in-class treatment for adults with UC, and the European Medicines Agency's Committee has given a positive opinion for its use in Europe. Regulatory decisions are anticipated globally in 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.11%
Tags
none
-
Rhea-AI Summary

Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2023 financial results on April 27, 2023, followed by a conference call at 10 a.m. Eastern time. The event will provide insights into the company’s financial performance.

Investors and the public can access a live webcast of the call through Lilly's investor relations website. A replay will also be available post-event. With nearly 150 years in the industry, Lilly is committed to delivering innovative medicines and clinical trials, focusing on significant health challenges including diabetes, obesity, Alzheimer’s disease, and various cancers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.65%
Tags
Rhea-AI Summary

Eli Lilly and Company (NYSE: LLY) announced that its oncology portfolio data will be presented at the AACR Annual Meeting in Orlando from April 14-19, 2023. Key presentations include Phase 1 results for LY3537982, a KRAS G12C inhibitor, and LY3410738, an IDH inhibitor, alongside a Phase 2 study of Verzenio for treating metastatic castration-resistant prostate cancer. Preclinical data for Jaypirca's unique binding mechanism will also be shared. The sessions will discuss significant new findings that could impact future treatments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.73%
Tags
none
-
Rhea-AI Summary

Eli Lilly's solanezumab has failed to show efficacy in slowing cognitive decline in preclinical Alzheimer's disease, as reported in the A4 Study. The trial, involving over 1,100 participants aged 65 to 85, demonstrated that solanezumab did not meet primary or secondary endpoints, nor did it clear amyloid plaques in the brain. Results indicated a cognitive decline of -1.69 for solanezumab compared to -1.4 for the placebo (p-value 0.26). Lilly continues its commitment to Alzheimer’s research, focusing on new treatments like donanemab and remternetug, which are currently in Phase 3 trials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.38%
Tags
none
-
Rhea-AI Summary

The U.S. FDA has accepted a supplemental New Drug Application (sNDA) for Jardiance® (empagliflozin), which aims to lower blood sugar in children aged 10-17 with type 2 diabetes. This application is supported by phase III results from the DINAMO trial, showing a significant A1c reduction of 0.84% compared to placebo over 26 weeks. If approved, Jardiance would be the first SGLT2 inhibitor for this age group. Currently, type 2 diabetes is increasingly affecting youth, impacting approximately 39,000 people under 20 in the U.S. Safety data aligns with existing profiles, with no new risks identified.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.61%
Tags
none

FAQ

What is the current stock price of Lilly Eli & Co (LLY)?

The current stock price of Lilly Eli & Co (LLY) is $813.48 as of March 14, 2025.

What is the market cap of Lilly Eli & Co (LLY)?

The market cap of Lilly Eli & Co (LLY) is approximately 725.8B.

What is the primary focus of Lilly Eli & Co?

Lilly Eli & Co is focused on developing, manufacturing, and globally distributing innovative therapeutic medicines across areas like diabetes, oncology, immunology, and neuroscience.

How does the company generate its revenue?

The company generates revenue through its extensive R&D efforts, production of high-quality medicines, and worldwide sales, supported by a robust manufacturing network and strategic global partnerships.

What sets Lilly Eli & Co apart in the pharmaceutical industry?

Its long history of innovation, combined with cutting-edge research, advanced manufacturing capabilities, and a strong commitment to quality, positions Lilly Eli & Co as a trusted and pioneering leader in healthcare.

How does Lilly Eli & Co ensure the quality and safety of its products?

The company follows rigorous clinical trial protocols and regulatory standards, ensuring that every product meets the highest levels of safety and efficacy before reaching patients around the world.

Where is Lilly Eli & Co headquartered?

Lilly Eli & Co is headquartered in Indianapolis, Indiana, and operates an extensive global network to support its manufacturing and research activities.

What role does research and development play at Lilly Eli & Co?

R&D is central to the company’s business model, driving innovation in drug discovery, advanced biotechnology applications, and the development of novel therapies to address critical health challenges.

How does Lilly Eli & Co contribute to global healthcare?

By providing innovative, high-quality medicines across diverse therapeutic areas and maintaining an efficient global distribution network, the company helps improve patient outcomes and supports health systems worldwide.

What are some key industry keywords associated with the company?

Key terms include pharmaceutical innovation, biotechnology, therapeutics, research and development, advanced manufacturing, and clinical excellence.
Lilly Eli & Co

NYSE:LLY

LLY Rankings

LLY Stock Data

725.80B
946.07M
0.15%
83.27%
0.8%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States
INDIANAPOLIS